Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.45% is 55% below its 2-year average of 12.23%, near the low end of its 2-year range (0.00%–60.53%).
As of the fiscal period ended Tuesday, June 30, 2026. 62.74% below its 12-month average of 14.62%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.45%.
DEBT TO ASSETS RATIO
5.45%
DEBT TO ASSETS RATIO AVG TTM
14.62%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-62.74%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 589 covered companies
CURRENT VS SECTOR MEDIAN
+5346.64%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$6.91M
Debt to Assets Ratio
5.45%
TTM Avg
14.62%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.91M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.05M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.76M
Debt to Assets Ratio
0.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.53M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.36M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $6.91M | 5.45% | 14.62% | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.91M | 0.11% | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.83M | 0.00% | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.05M | 0.02% | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | 0.54% | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | 0.00% | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.25M | 0.00% | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.53M | 0.07% | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.36M | 0.00% | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.47M | 0.04% | N/A | N/A | N/A |
Debt/Assets
5.4%
Debt/Equity
0.06
Current Ratio
45.95
Interest Coverage
-496.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.45% |
| 2026-03-31 | 3.70% |
| 2025-12-31 | 2.99% |
| 2025-09-30 | 0.42% |
| 2025-06-30 | 60.53% |
| 2025-03-31 | 37.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
